Pomalidomide-amino-PEG4-NH2 hydrochloride is primarily utilized in the development of targeted cancer therapies, particularly in the field of proteolysis-targeting chimeras (PROTACs). Its structure features pomalidomide as an E3 ubiquitin ligase-recruiting moiety (binding to cereblon), connected via an amino-PEG4 linker to a free amine group (NH2) that can be conjugated to a target protein-binding ligand. This facilitates the degradation of specific disease-causing proteins by proximity-induced ubiquitination, offering a promising approach for treating conditions like multiple myeloma and other cancers. Additionally, its PEG4 spacer enhances solubility and stability, making it suitable for use in bioconjugation and drug delivery systems. This compound is also explored in research for its potential in immunotherapy and as a tool for studying protein-protein interactions in cellular pathways.